A string of longevity meetings (ARDD, Biomarkers of Aging, etc.) just wrapped up in Boston and I have to assume some folks here showed up. Please share any highlights!

[ Removed by Reddit on account of violating the content policy. ]

For decades, reproductive biology and mainstream medicine have treated the ovary almost entirely through the lens of reproduction: periods, pregnancy, and menopause. Once menopause hits, the conventional assumption has been that the organ simply becomes defunct or “retired.”
https://news.northwestern.edu/stories/2026/08-2/reshaping-how-we-think-about-the-ovary-and-aging

The post by Eric Topol explains a recent paper that illuminates biological processes that drive epigenetic drift, which epigenetic clocks can measure across mammals. The original paper lays out the importance of PRC2 in this process (paywalled): https://www.nature.com/articles/s41586-026-10955-0

A Finnish twin study looked at whether living conditions and lifestyle from adolescence to early adulthood were linked to biological aging measured from blood at around age 22.

One interesting finding was that higher youth unemployment in the residential area was linked to faster biological aging. Some measures of nearby vegetation were linked to slower aging, although the environmental results were not always straightforward.

This was an observational study, so it can’t show that these conditions caused faster or slower aging. Biological aging was also measured only once, in early adulthood.

I run a small independent research publication called HUMANUMi, and I wrote more about the study here:

https://humanumi.com/new-study-living-conditions-in-youth-are-linked-to-biological-aging/

Oracle and the Buck Institute for Research on Aging are collaborating to advance intelligence into age-related disease and support discoveries that can extend the healthy years of life. Buck will leverage Oracle Life Sciences Data Intelligence, which encompasses 122 million+* de-identified longitudinal Oracle Health Real-World Data records and advanced analytics to research biomarkers that aim to enable early detection and targeted intervention for aging-related complications. The research will also be used to pursue qualification for the first FDA-grade "Intrinsic Capacity Score," a vitality score for healthy aging.

Decoding Age-Related Illnesses
The Buck Institute serves as one of the analytics and bioinformatics engines for the Stanford University-led Transforming Health: Reclaiming Intrinsic Vitality for Everyone (THRIVE) consortium of scientists. THRIVE is a component of the PROactive Solutions for Prolonging Resilience (PROSPR) program from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services. The THRIVE team's goal is to develop a validated measure of physical and mental capacity designed to help predict long-term health trajectories and enable earlier interventions for age-related decline in a patient's health journey.

The study will begin enrolling this fall, and the molecule has been used in several dermatology trials already. Marco Quarta is the most well-known researcher at Rubedo, having studied cellular senescence for decades.

The thymus involutes mostly to fat by age 60, which leads to a decline in immune function, as the thymus trains immune cells to protect one's own cells and attack foreign objects. FibroBiologics aims to use fibroblasts, rather than stem cells, to mitigate thymic disorders and age-related thymic decline.

Aspen Neuroscience is currently evaluating its personalized cell therapy in a clinical trial for Parkinson's disease.

The company uses a patient’s own skin cells, converts them into induced pluripotent stem cells (iPSCs), and differentiates them into dopamine-producing neuron precursors. They have received Fast Track and Regenerative Medicine Advanced Therapy (RMAT) from the FDA.

https://aspenneuroscience.com/technology-overview/

Venki Ramakrishnan is a molecular biologist and Nobel laureate. He recently became interested biomedical research on the biology of aging and wrote a book on the subject. He supports scientific research in the field but is skeptical of the feasibility of dramatically increased lifespan.

LOY-003 is a once daily oral tablet focused on addressing this “big dog, short life” problem many dog owners and vets are all too familiar with. Similar to LOY-001, which was the first drug to achieve an RXE acceptance for lifespan extension in any species, LOY-003 reduces GH and IGF-1 levels with the aim of preserving quality of life and extending lifespan in large- and giant-breed dogs. The FDA now agrees that LOY-003 can reasonably be expected to be effective at achieving this.